Owing to the increasing incidences of diabetic patients there is a rise in the periodontal therapeutic market Whereas the rising prevalence of periodontal disorders and technological advancement in therapeutics are some factors positively impacting on the growth of this market.
Periodontal continues to be one of the major causes of tooth loss and a major oral health issue. The disease is common in both developed and developing countries, affecting nearly 20 to 50% of the global population. Over the years, different periodontal therapies have come up with a high degree of effectivity. Both surgical and non-surgical treatment options available.
The onset of periodontal issues could be triggered by poor oral hygiene, diabetes mellitus, stress, smoking and hormonal changes in females. The incidence rate has continued to grow, which is also driving the demand for periodontal therapeutic. As per World Health Organization (WHO), there is a high incident rate of gingival bleeding in adults worldwide. Meanwhile, 10 to 15% of adults are affected with deep periodontal pockets (6 mm or more) globally.
Major drivers of the global periodontal therapeutic market include rising geriatric population and growing worldwide healthcare spending. Nevertheless, poor level of awareness and negligence towards oral hygiene, especially in third-world countries are among the key bottlenecks for the market.
Some of the key players in the global periodontal therapeutic market are, Tolmar Inc, Eli Lilly Company, Align Technology Inc., Dentsply International, 3M-ESPE, Ultradent Products Inc., Nobel Biocare Holdings AG, Glidewell Laboratories, Inc., Orapharma, Kaken Pharmaceutical, Valeant Pharmaceuticals Int. Inc, Den-Mat Holdings, Mallinckrodt Pharmaceuticals, Purdue Pharma L.P., Teva Pharmaceutical Industries Limited, and Fibrocell Sciences Inc.
The global periodontal therapeutic market has been segmented on basis of treatment type, types of periodontal and end-users. Based on treatment types market is segmented into two segments such as systematic antibiotics and local antibiotics. Systematic antibiotics are further sub-segmented into doxycycline, minocycline, metronidazole, and others. Local antibiotics are further segmented into arestin, chlorhexidine, and others. On basis of types of periodontal scalers, the market is segmented into three types such as chronic periodontitis, aggressive periodontitis, necrotizing periodontal disease. On basis of end-user market is further is segmented into dental clinics and hospitals
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
Global Periodontal Therapeutic Market: Regional Segmentation
Key regions covered in MRFR’s report include Asia Pacific, Europe, North America and the Middle East and Africa (MEA). In terms of revenue, North America accounts for the predominant market share. This is mainly owing to the higher prevalence of periodontal diseases among the elderly population in countries such the U.S. and Canada. The data released by the Centers for Disease Control and Prevention (CDC) reveals that nearly 50% of people in the U.S. aged 30 of older suffer from periodontitis as advanced form of periodontal disease. This is equivalent to around 64.7 Mn American with periodontal diseases.
Europe is also viewed as an important market for periodontal therapeutic. The prevalence rate in Europe has increased in recent years. Factors such as an expanding elderly population, availability of advanced healthcare services and effective reimbursement policies are playing an important role in driving the market growth in Europe. The market in Europe is expected to exhibit a steady growth during the forecast period.
Asia Pacific is the third largest market for periodontal therapeutic and is expected to witness a strong growth over the next couple of years. A large patient population coupled with increasing healthcare expenditure will create significant opportunities for the market to grow in APAC during the forecast period.
The MEA market holds significant potentials for growth with GCC countries at the forefront of it. Rising standard of healthcare, growing level of awareness and introduction of favourable policies are factors propelling the market in MEA.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071